Advertisement
Singapore markets open in 1 minute

  • Straits Times Index

    3,265.95
    +1.42 (+0.04%)
     

  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     

  • Dow

    39,387.76
    +331.36 (+0.85%)
     

  • Nasdaq

    16,346.26
    +43.46 (+0.27%)
     

  • Bitcoin USD

    62,802.11
    +1,392.04 (+2.27%)
     

  • CMC Crypto 200

    1,349.63
    +49.53 (+3.81%)
     

  • FTSE 100

    8,381.35
    +27.30 (+0.33%)
     

  • Gold

    2,353.90
    +13.60 (+0.58%)
     

  • Crude Oil

    79.65
    +0.39 (+0.49%)
     

  • 10-Yr Bond

    4.4490
    -0.0430 (-0.96%)
     

  • Nikkei

    38,691.20
    +617.22 (+1.62%)
     

  • Hang Seng

    18,537.81
    +223.91 (+1.22%)
     

  • FTSE Bursa Malaysia

    1,601.22
    -3.53 (-0.22%)
     

  • Jakarta Composite Index

    7,088.79
    -34.81 (-0.49%)
     

  • PSE Index

    6,542.46
    -116.72 (-1.75%)
     

US FDA approves Otsuka's blood pressure treatment device for use

Reuters
·1-min read

Nov 8 (Reuters) - The U.S. Food and Drug Administration (FDA) approved the use of a device made by an Otsuka Holdings unit in a type of surgery to treat high blood pressure, the company said on Wednesday.

The approval for Paradise Ultrasound Renal Denervation comes after an FDA panel backed its use.

The device is made by Japanese company Otsuka's unit ReCor and is indicated for use in patients whose hypertension, or high blood pressure, cannot be controlled with drugs.

ReCor's device, which is a balloon-like structure inside a catheter, is inserted through a small cut into the kidney's arteries and sends ultrasound energy to burn nerves that are believed to control blood pressure.

The surgery has been previously approved in Europe and other parts of the world. (Reporting by Gursimran Kaur in Bengaluru; Editing by Subhranshu Sahu)